Welcome to our dedicated page for MetLife SEC filings (Ticker: MET), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MetLife, Inc. filings document the regulatory record of a Delaware financial services company with NYSE-listed common stock and preferred securities, including depositary shares tied to Series E and Series F preferred stock. Recent Form 8-K reports furnish earnings releases, quarterly financial supplements, total assets under management fact sheets and Regulation FD disclosures related to variable investment income.
The filings also cover capital-structure actions such as subordinated debenture issuance and preferred stock dividend declarations. Proxy materials describe board composition, committee assignments, executive compensation and shareholder voting matters, while material-event reports record governance changes and other corporate disclosures.
MetLife Inc. director Daniel S. Glaser reported an acquisition of 273 shares of common stock as a grant under non-management director compensation arrangements. The grant was valued at $75.34 per share, and he elected to defer receipt of these shares into the MetLife Deferred Compensation Plan for Non-Management Directors.
Following this award, Glaser directly holds 1,380 common shares. The filing also notes 198 common shares held indirectly in a Grantor Retained Annuity Trust, which were previously reported as directly owned due to an administrative error and are now correctly classified as indirectly held.
MetLife Inc. director Daniel S. Glaser updated his initial ownership report for the company’s common stock. The amended Form 3 shows he holds 1,107 shares directly and 198 shares indirectly through a Grantor Retained Annuity Trust (GRAT).
The footnote explains the GRAT-held shares were previously reported as directly owned due to an administrative error, and this amendment corrects the ownership classification without indicating any new purchase or sale of shares.
MetLife director Diana McKenzie reported a small compensation-related share increase. She acquired 189 shares of MetLife common stock on an imputed basis at $70.60 per share through reinvested dividends in the MetLife Deferred Compensation Plan for Non-Management Directors. Following this grant, she directly holds 23,751 common shares, reflecting routine deferred compensation rather than an open-market purchase.
MetLife Inc. director Jeh C. Johnson reported an acquisition of 65 shares of MetLife common stock on March 10, 2026 at an imputed price of $70.60 per share. The filing states this resulted from imputed reinvestment of dividends on deferred shares under MetLife’s Deferred Compensation Plan for Non-Management Directors.
After this award, Johnson directly holds 8,129 MetLife common shares. The footnote explains that the deferred shares represent MetLife common stock that has become payable, but whose receipt Johnson has chosen to defer.
MetLife director Robert Glenn Hubbard received 771 shares of Common Stock at $70.60 per share as a grant under the MetLife Deferred Compensation Plan for Non-Management Directors.
The footnote explains this was an imputed reinvestment of dividends on deferred shares. After this compensation-related acquisition, he directly holds 104,630 MetLife shares.
MetLife Inc director Laura J. Hay acquired 40 shares of common stock on March 10, 2026 at $70.60 per share. The filing describes this as a grant or award, specifically an imputed reinvestment of dividends on deferred shares under MetLife’s Deferred Compensation Plan for Non-Management Directors.
Following this transaction, Hay directly holds 4,971 shares of MetLife common stock. The deferred shares have become payable, but she has chosen to defer actual receipt of the shares.
MetLife Inc. director William E. Kennard acquired additional common stock through a compensation-related award. On 2026-03-10, he received 365 shares of MetLife common stock at $70.60 per share, reflecting imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors.
After this award, Kennard directly holds 45,780 MetLife common shares. He also has an additional 10 shares held indirectly through the MetLife Policyholder Trust, which was established to hold stock allocated to eligible policyholders. These transactions are non-open-market and arise from director compensation and trust holdings rather than discretionary buying or selling.
MetLife director Christian Stephane Mumenthaler acquired 17 shares of common stock as a grant under the MetLife Deferred Compensation Plan for Non-Management Directors. The award, recorded at a reference price of $70.60 per share, brings his directly held MetLife shares to 2,125.
MetLife Inc director Carla A. Harris reported acquiring 43 shares of common stock on March 10, 2026 at $70.60 per share. The filing explains this was an imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors.
After this award, Harris directly holds 9,764 MetLife common shares. The transaction reflects compensation-related dividend reinvestment rather than an open-market stock purchase.
MetLife, Inc. filed a report confirming a previously announced first quarter 2026 dividend on its floating rate non-cumulative preferred stock, Series A. The dividend is $0.31501229 per share on shares with a $25 liquidation preference.
The company stated that the dividend will be payable on March 16, 2026, to shareholders of record as of Friday, February 27, 2026, because the normal record date of March 1, 2026 falls on a Sunday. The New York Stock Exchange had not yet set an ex-dividend date for the Series A preferred stock at the time of the announcement and is expected to set it following this confirmatory announcement.